IFNA2 and chronic hepatitis C virus infection: Amantadine and its derivative rimantadine, in combination with interferon α2b (IFNα2b) and ribavirin, have shown higher efficacy in the treatment of chronic hepatitis C in non-responders to IFNα2b than the combination of IFNα2b with ribavirin, measured as the end-of-treatment response (ETR), according to two literature reviews [12,13].